Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Jaina Patel was in her early 30s when a bout of bronchitis led to hear losing weight, her job and eventually her sense of smell - until a clinical trial worked wonders ...

Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), succeeding in a Phase IIb trial but failing in a Phase III study.

Topics covered include rising food allergies in children, the psychological burden of chronic allergic diseases, predictors ...

Dupilumab Improves Clinical and Microbial Outcomes in Paediatric ... Moreover, those with GSM-induced anaphylaxis were ...

We thank Sara Osborne and colleagues for their interest in our trial.1 Ligelizumab phase 3 studies in patients with chronic spontaneous urticaria (CSU)1 were done with a study design and in ...

Cameron Santoro is an associate editor for The American Journal of Managed Care® (AJMC®), AJMC.com, and The Center for Biosimilars®.